/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

L

L. Puig

Universitat Autònoma de Barcelona(ES)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

1.0K

Papers

29.5K

Citations

74

h-index

454

i10-index

L. Puig is an academic researcher from Universitat Autònoma de Barcelona. The author has contributed to research in topics: Psoriasis: Treatment and Pathogenesis & Dermatology and Skin Diseases & Health Systems, Economic Evaluations, Quality of Life. The author has an h-index of 74, co-authored 864 publications.

ORCID: 0000-0001-6083-0952

Research Topics

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Health Systems, Economic Evaluations, Quality of Life Autoimmune Bullous Skin Diseases Pharmaceutical studies and practices

Papers by this author

works

Epidemiology of atopic dermatitis in adults: Results from an international survey

2018 · Allergy · 849 citations

https://doi.org/10.1111/all.13401

S. Barbarot S. Auziere A. Gadkari Giampiero Girolomoni

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

2013 · The Lancet · 789 citations

https://doi.org/10.1016/s0140-6736(13)60594-2

Iain B. McInnes Arthur Kavanaugh Alice B. Gottlieb L. Puig

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

2014 · Annals of the Rheumatic Diseases · 654 citations

https://doi.org/10.1136/annrheumdis-2013-204655

Christopher T. Ritchlin Proton Rahman Arthur Kavanaugh Iain B. McInnes

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

2018 · The Lancet · 627 citations

https://doi.org/10.1016/s0140-6736(18)31713-6

Kenneth B. Gordon Bruce Strober Mark Lebwohl Matthias Augustin

European consensus statement on phenotypes of pustular psoriasis

2017 · Journal of the European Academy of Dermatology and Venereology · 419 citations

https://doi.org/10.1111/jdv.14386

Alexander A. Navarini A. David Burden Francesca Capon Ulrich Mrowietz

Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial

2016 · International Journal of Antimicrobial Agents · 106 citations

https://doi.org/10.1016/j.ijantimicag.2016.05.021

Jaime Lora-Tamayo Gorane Euba Javier Cobo Juan Pablo Horcajada

Research topics

topics

Psoriasis: Treatment and Pathogenesis

Dermatology and Skin Diseases

Health Systems, Economic Evaluations, Quality of Life

Autoimmune Bullous Skin Diseases

Pharmaceutical studies and practices

Chat about Author

Papers

Chat

Click to start Chat